ReviewPharmaceutics2017
Augmented Renal Clearance in Critical Illness: An Important Consideration in Drug Dosing.
Review in Pharmaceutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07410624 (Augmented Renal Clearance in Neurocritical Care Population), which is not on this map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Augmented Renal Clearance in Neurocritical Care Population: A Prospective Multicenter Study
Who cites it
78 citing papers in PubMed.
- Investigation of pharmacokinetic and clinical outcomes of various meropenem regimens in patients with ventilator-associated pneumonia and augmented renal clearance.European journal of clinical pharmacology · 2022Trial
- Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial.Critical care (London, England) · 2021Trial
- Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis.Pharmacotherapy · 2026Article
- Machine learning-based risk prediction of 28-day mortality for sepsis patients with augmented renal clearance.Scientific reports · 2026Article
- Prognostic Implications of Vancomycin Therapeutic Drug Monitoring for Critically Ill Stroke Patients: Evidence From a Subtype-Oriented Analysis.CNS neuroscience & therapeutics · 2026Article
- The long walk to a short half-life: the discovery of augmented renal clearance and its impact on antibiotic dosing.The Journal of antimicrobial chemotherapy · 2025Review
- Levetiracetam Dosing Optimization in Neurocritical Care Population: Neuro-ARC Study.Neurocritical care · 2025Observational
- β-Lactam/β-Lactamase Inhibitor Combinations in Sepsis-Associated Acute Kidney Injury and Renal Replacement Therapy.Antibiotics (Basel, Switzerland) · 2025Review
- Article
- Machine learning for the prediction of augmented renal clearance (ARC) in patients with sepsis in critical care units.Scientific reports · 2025Article
- The Impact of Augmented Renal Clearance on the Pharmacokinetics of Levetiracetam in Critically Ill Patients: A Literature Review.Journal of clinical pharmacology · 2025Review
- The Definition, Prevalence, and Risk Factors of Augmented Renal Clearance in Adult Patients on Antimicrobial Therapy: A Scoping Review.Infectious diseases & clinical microbiology · 2025Article
- Prevalence and Risk Factors for Augmented Renal Clearance in Neurocritical Ill Patients.Journal of clinical laboratory analysis · 2025Observational
- Utilizing gentamicin concentrations to estimate glomerular filtration rate in intensive care unit patients.Scientific reports · 2025Article
- Development of a Population Pharmacokinetic Model of Levofloxacin in Healthy Adults and Identification of Optimal Dosing Regimens.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Safe and effective use of vancomycin.Australian prescriber · 2025Review
- The Development and Validation of a Simple HPLC-UV Method for the Determination of Vancomycin Concentration in Human Plasma and Application in Critically Ill Patients.Molecules (Basel, Switzerland) · 2025Article
- Preoperative serum creatinine changes and acute kidney injury in patients underwent cardiac surgery.Frontiers in medicine · 2025Article
- Pharmacotherapy variability and precision medicine in neurocritical care.Frontiers in neurology · 2025Review
- The Impact of Augmented Renal Clearance on Vancomycin Pharmacokinetics and Pharmacodynamics in Critically Ill Patients.Journal of clinical medicine · 2024Review
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Augmented renal clearance (ARC) is a manifestation of enhanced renal function seen in critically ill patients. The use of regular unadjusted doses of renally eliminated drugs in patients with ARC might lead to therapy failure. The purpose of this scoping review was to provide and up-to-date summary of the available evidence pertaining to the phenomenon of ARC. A literature search of databases of available evidence in humans, with no language restriction, was conducted. Databases searched were MEDLINE (1946 to April 2017), EMBASE (1974 to April 2017) and the Cochrane Library (1999 to April 2017). A total of 57 records were included in the present review: 39 observational studies (25 prospective, 14 retrospective), 6 case reports/series and 12 conference abstracts. ARC has been reported to range from 14-80%. ARC is currently defined as an increased creatinine clearance of greater than 130 mL/min/1.73 m² best measured by 8-24 h urine collection. Patients exhibiting ARC tend to be younger (<50 years old), of male gender, had a recent history of trauma, and had lower critical illness severity scores. Numerous studies have reported antimicrobials treatment failures when using standard dosing regimens in patients with ARC. In conclusion, ARC is an important phenomenon that might have significant impact on outcome in critically ill patients. Identifying patients at risk, using higher doses of renally eliminated drugs or use of non-renally eliminated alternatives might need to be considered in ICU patients with ARC. More research is needed to solidify dosing recommendations of various drugs in patients with ARC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.